跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Selective Killing: How Chemotherapy Harms Cancer Cells More Than Normal Cells

1The Selectivity Problem: Why Preferential Killing Is Possible but Imperfect2Proliferation as the Primary Vulnerability: Cell-Cycle Dependence3Antimetabolites and the S-Phase Trap4Microtubule Poisons and Mitotic Arrest5DNA-Damaging Agents: Alkylators, Crosslinkers, and Topoisomerase Poisons6The DNA-Damage Response and the Decision to Die7Why Selectivity Fails: Normal-Tissue Toxicity and the Limits of the Window8Resistance: How Tumors Escape and What It Reveals About Selectivity9Widening the Window: Clinical Strategies That Exploit Selectivity
Why Selectivity Fails: Normal-Tissue Toxicity and the Limits of the Window

The Ceiling: Why Dose-Limiting Toxicity Sets the Window

2 / 2
Think about what happens as you push the dose up. The tumor response rises, but so does toxicity in the most vulnerable normal tissue. The toxicity that appears first is the dose-limiting one, and the highest dose that keeps it acceptable is the maximum tolerated dose. That is the ceiling. It is not set by how much drug the tumor needs; it is set by how much the normal tissue can take. Now look at the rescue strategies. Growth factor, leucovorin, amifostine, dexrazoxane — none of them makes the tumor more sensitive. Each one raises the tolerated dose by protecting or repairing normal tissue. That is the only lever you have when the tumor and the normal tissue share the same target.
0:00 / 0:00

Dose-limiting toxicity is the toxicity that appears first as dose rises and prevents further escalation. The maximum tolerated dose is the highest dose that keeps that toxicity at an acceptable grade. Because the tumor and the vulnerable normal tissue share the same damage-and-death pathway, the normal-tissue threshold is often reached at a dose the tumor could survive. The therapeutic index is therefore capped by the normal-tissue threshold, not by tumor sensitivity.

Strategies that raise the tolerated dose

  • Granulocyte colony-stimulating factor shortens neutropenia and allows the next cycle to be delivered on schedule.
  • Leucovorin bypasses the methotrexate block in normal cells, reducing mucosal and marrow toxicity.
  • Amifostine scavenges reactive oxygen species in normal tissue, reducing radiation and some chemotherapy toxicity.
  • Dexrazoxane chelates iron and reduces anthracycline cardiotoxicity.

Rescue and supportive care do not make the tumor more sensitive. They raise the dose ceiling from the normal-tissue side, which is the only way to widen the window when the tumor and the normal tissue share the same molecular target.

上一页2 / 2下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion